Market revenue in 2023 | USD 728.6 million |
Market revenue in 2030 | USD 1,060.9 million |
Growth rate | 5.5% (CAGR from 2023 to 2030) |
Largest segment | Synthetic/ blend of natural & synthetic |
Fastest growing segment | Natural |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Natural, Synthetic/ Blend of Natural & Synthetic |
Key market players worldwide | Fairhaven Health, Vitabiotics, Mankind Pharma, extreme V, Coast Science, Orthomol, Exeltis, bioNova, Innovamed, PlusPlus LifeSciences, Eu Natural |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fertility supplements market will help companies and investors design strategic landscapes.
Synthetic/ blend of natural & synthetic was the largest segment with a revenue share of 88.92% in 2023. Horizon Databook has segmented the North America fertility supplements market based on natural, synthetic/ blend of natural & synthetic covering the revenue growth of each sub-segment from 2018 to 2030.
Due to the rising rate of infertility and increased public awareness of general health, North America is predicted to experience significant growth over the forecast period. Given that these variables are linked to both male and female infertility, the majority of people in the area have a tendency to use fertility supplements because they are an excellent source of micronutrients and support fertility.
The success rates of in vitro fertilization (IVF) in the U.S. provide useful insight into the significance of timing. A report published by The Society for Assisted Reproductive Technology states that for women under 35, live births occurred in 55% of IVF cycle starts.
The rate for women in the 35–37 age group was 41%, and for those in the 38–40 age group, it was 26.8%. The success rate for women between the ages of 41 and 42 was only 13.4%, whereas the rate for women over 42 was 4.3%.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America fertility supplements market , including forecasts for subscribers. This continent databook contains high-level insights into North America fertility supplements market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account